Related Experiment Videos
[Targeting of antitumor drugs with monoclonal antibodies]
1Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05.
Abstract:
About forty years ago, immuno-targeting of antitumor drugs has been addressed as a way to improve their selectivity towards tumor cells. Despite the wide display of researches to solve inherent problems within this approach, rare were the immuno-conjugates which reached the clinical level. In any case, none of them was introduced in chemotherapy. However, there was a renewal of activity for the last ten years, due, in part, to the access to very highly cytotoxic-containing immuno-conjugates such as those elaborated from maytansinoides, enediynes or intercalating agents CC1065. It was also due to the design of the Adept concept. This antibody-directed enzyme prodrug therapy is based upon the use of monoclonal antibody to target an enzyme at the tumor cell surface which ultimately is expected to selectively deliver an antitumor drug from a suitable inactive prodrug. In both cases, clinical trials are in progress and one can expect that, at least, some immuno-conjugates will be soon introduced in cancer chemotherapy.
Insights
Immuno-conjugates, using antibody-directed enzyme prodrug therapy (ADEPT), are advancing cancer chemotherapy. These targeted therapies show promise for improved selectivity and clinical introduction in cancer treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Context:
- Immuno-targeting of antitumor drugs aims to enhance selectivity for tumor cells.
- Despite decades of research, few immuno-conjugates have reached clinical application in chemotherapy.
- Recent advancements include highly cytotoxic agents and Antibody-Directed Enzyme Prodrug Therapy (ADEPT).
Purpose:
- To review the progress and potential of immuno-conjugates and ADEPT in cancer chemotherapy.
- To highlight the development of novel immuno-conjugates utilizing potent cytotoxic payloads.
- To discuss the clinical prospects of antibody-based targeted drug delivery systems.
Summary:
- Immuno-conjugates, developed over 40 years, aim to improve antitumor drug selectivity.
- Recent progress includes highly cytotoxic agents like maytansinoids and the Antibody-Directed Enzyme Prodrug Therapy (ADEPT) concept.
- Clinical trials are underway for these advanced immuno-conjugate strategies.
Impact:
- Immuno-conjugates and ADEPT are poised to be introduced into clinical cancer chemotherapy.
- These targeted approaches offer potential for more effective and selective cancer treatment.
- Continued research may lead to novel therapeutic options for various cancers.